Supplementary tables for Estimated Vaccination Coverage with Selected Vaccines and Doses Among Adolescents Aged 13–17 Years — National Immunization Survey–Teen (NIS-Teen), United States, 2019
SUPPLEMENTARY TABLE 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years,* by race/ethnicity† — National Immunization Survey–Teen (NIS-Teen), United States, 2019.
| Vaccines | Race/Ethnicity, % (95% CI)§ | |||||
|---|---|---|---|---|---|---|
| White only, non-Hispanic
(n = 11,883)
|
Black only, non-Hispanic (n = 1,367)
|
Hispanic
(n = 3,466)
|
American Indian/Alaska Native only, non-Hispanic
(n = 237)
|
Asian, non-Hispanic
(n = 607)
|
Multiracial, non-Hispanic (n = 1,164)
|
|
| Tdap¶≥1 dose | 91.1 ( 90.1 – 92.1) |
89.1 ( 85.7 – 91.8) |
88.5 ( 85.6 – 90.9) |
90.7 ( 83.8 – 94.9) |
89.7 ( 83.7 – 93.6) |
91.6 ( 87.5 – 94.5) |
| MenACWY** | ||||||
| ≥1 dose | 88.4 ( 87.3 – 89.5) |
89.4 ( 86.8 – 91.6) |
89.3 ( 86.9 – 91.4) |
85.3 ( 71.8 – 93.0) |
93.3 ( 89.2 – 95.9)†† |
90.0 ( 86.3 – 92.7) |
| ≥2 doses §§ | 53.9 ( 49.7 – 58.0) |
57.2 ( 45.3 – 68.3) |
52.4 ( 42.0 – 62.6) |
NA | 61.8 ( 41.9 – 78.4) |
39.4 ( 28.4 – 51.6)†† |
| HPV§§vaccine coverage by doses | ||||||
| ≥ 1 dose | 68.3 ( 66.8 – 69.9) |
72.0 ( 67.8 – 75.9) |
76.8 ( 73.3 – 79.9)†† |
71.1 ( 58.2 – 81.3) |
74.8 ( 68.1 – 80.5) |
73.0 ( 67.8 – 77.6) |
| HPV UTD¶¶ | 51.6 ( 49.9 – 53.3) |
54.3 ( 49.8 – 58.8) |
58.1 ( 54.0 – 62.0)†† |
57.5 ( 45.3 – 68.8) |
64.7 ( 57.3 – 71.4)†† |
55.3 ( 49.6 – 60.9) |
| ≥2 MMR vaccine doses | 93.1 ( 92.0 – 94.0) |
92.5 ( 90.1 – 94.4) |
89.0 ( 85.7 – 91.6)†† |
92.7 ( 84.5 – 96.7) |
93.0 ( 88.9 – 95.7) |
93.4 ( 89.5 – 95.9) |
| ≥2 Hepatitis A doses*** | 75.7 ( 74.2 – 77.0) |
78.1 ( 74.5 – 81.3) |
78.5 ( 74.6 – 82.0) |
84.0 ( 69.9 – 92.3) |
86.4 ( 80.5 – 90.8)†† |
77.1 ( 72.0 – 81.4) |
| ≥3 Hepatitis B doses | 93.8 ( 93.1 – 94.5) |
91.2 ( 88.7 – 93.2)†† |
87.3 ( 83.6 – 90.2)†† |
93.5 ( 85.7 – 97.2) |
90.3 ( 85.4 – 93.6) |
94.1 ( 91.7 – 95.9) |
| Varicella | ||||||
| History of varicella††† | 8.8 ( 7.9 – 9.7) |
6.4 ( 4.7 – 8.5)†† |
11.3 ( 9.5 – 13.4)†† |
NA | 8.9 ( 5.9 – 13.2) |
9.3 ( 6.6 – 13.0) |
| Among adolescents with no history of varicella: | ||||||
| ≥1 dose vaccine | 96.1 ( 95.5 – 96.7) |
95.4 ( 93.4 – 96.8) |
93.5 ( 90.4 – 95.6) |
94.2 ( 85.6 – 97.8) |
94.5 ( 90.3 – 96.9) |
96.5 ( 94.4 – 97.8) |
| ≥2 doses vaccine | 92.0 ( 90.9 – 93.0) |
92.2 ( 89.8 – 94.0) |
86.8 ( 83.0 – 89.8)†† |
92.1 ( 83.9 – 96.3) |
92.6 ( 88.5 – 95.4) |
91.7 ( 87.4 – 94.7) |
| History of varicella or received ≥ 2 doses of varicella vaccine | 92.7 ( 91.7 – 93.6) |
92.7 ( 90.5 – 94.4) |
88.3 ( 84.8 – 91.0)†† |
92.7 ( 85.2 – 96.6) |
93.3 ( 89.5 – 95.8) |
92.5 ( 88.6 – 95.2) |
Abbreviations: CI = confidence interval; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; HPV = human papillomavirus; MMR = measles, mumps, and rubella vaccine; NA = not available (estimate not reported because unweighted sample size for the denominator was <30 or (95%CI half width / estimate) > 0.6)
* Adolescents (N = 18,788) in the 2019 NIS-Teen were born January 2001 through February 2007.
† Adolescent’s race/ethnicity was reported by their parent or guardian. Adolescents identified in this report as white, black, American Indian/Alaska Native, Asian, or multiracial were reported by the parent or guardian as non-Hispanic. Adolescents identified as multiracial had more than one race category selected. Adolescents identified as Hispanic might be of any race.
§ Estimates with 95% confidence intervals > 20 may not be reliable.
¶ Includes percentages receiving Tdap vaccine at or after age 10 years.
** Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.
†† Statistically significant difference (p<0.05) in estimated vaccination coverage by race/ethnicity; referent group was white, non-Hispanic adolescents.
§§ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.
¶¶ HPV UTD – Includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and there was at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
*** In July 2020, ACIP revised recommendations for Hepatitis A vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received Hepatitis A vaccine at any age. MMWR Recomm Rep 2020;69(No. RR-5):1–38.
††† By parent/guardian report or provider records.
SUPPLEMENTARY TABLE 2. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years,* by health insurance status† — National Immunization Survey–Teen (NIS-Teen), United States, 2019.
| Vaccines | Health Insurance Status, % (95% CI)§ | |||
|---|---|---|---|---|
| Private Insurance Only
(n = 11,183)
|
Any Medicaid
(n = 5,366)
|
Other Insurance
(n = 1,545)
|
Uninsured
(n = 694)
|
|
| Tdap¶≥1 dose | 91.2 ( 90.0 – 92.1) | 89.6 ( 87.3 – 91.5) | 90.3 ( 87.7 – 92.4) | 82.0 ( 76.3 – 86.5)†† |
| MenACWY** | ||||
| ≥1 dose | 89.2 ( 88.0 – 90.3) | 89.8 ( 88.0 – 91.4) | 86.6 ( 83.4 – 89.3) | 81.3 ( 75.4 – 86.0)†† |
| ≥2 doses §§ | 55.4 ( 50.3 – 60.3) | 54.1 ( 46.9 – 61.1) | 40.7 ( 30.3 – 52.1)†† | 52.2 ( 35.1 – 68.8) |
| HPV¶¶ vaccine coverage by doses | ||||
| ≥1 dose | 70.6 ( 68.9 – 72.2) | 75.0 ( 72.4 – 77.5)†† | 67.4 ( 62.9 – 71.7) | 60.3 ( 53.4 – 66.8)†† |
| HPV UTD*** | 53.1 ( 51.1 – 55.0) | 59.1 ( 56.2 – 62.0)†† | 49.6 ( 44.4 – 54.8) | 36.7 ( 30.4 – 43.5)†† |
| ≥2 MMR doses | 92.3 ( 91.1 – 93.4) | 91.6 ( 89.3 – 93.4) | 91.9 ( 89.3 – 93.9) | 88.7 ( 84.4 – 91.9) |
| ≥2 Hepatitis A doses††† | 77.1 ( 75.4 – 78.7) | 78.9 ( 76.5 – 81.1) | 76.1 ( 70.2 – 81.1) | 65.1 ( 58.1 – 71.6)†† |
| ≥3 Hepatitis B doses | 92.5 ( 91.2 – 93.6) | 91.2 ( 88.9 – 93.1) | 89.8 ( 86.6 – 92.4) | 86.5 ( 81.9 – 90.1)†† |
| Varicella | ||||
| History of varicella§§§ | 7.6 ( 6.7 – 8.6) | 9.5 ( 8.2 – 10.9)†† | 12.6 ( 9.6 – 16.5)†† | 19.6 ( 15.2 – 24.9)†† |
| Among adolescents with no history of varicella disease | ||||
| ≥1 dose vaccine | 95.8 ( 95.0 – 96.5) | 94.9 ( 92.8 – 96.4) | 94.8 ( 92.4 – 96.5) | 89.6 ( 83.1 – 93.8)†† |
| ≥2 doses vaccine | 91.0 ( 89.6 – 92.2) | 90.6 ( 88.0 – 92.6) | 91.3 ( 88.5 – 93.4) | 84.5 ( 78.0 – 89.4)†† |
| History of varicella or received ≥2 doses varicella vaccine | 91.7 ( 90.4 – 92.8) | 91.5 ( 89.1 – 93.3) | 92.4 ( 90.0 – 94.2) | 87.6 ( 82.2 – 91.5) |
Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.
* Adolescents (N = 18,788) in the 2019 NIS-Teen were born January 2001 through February 2007.
† Adolescents’ health insurance status was reported by parent or guardian. “Other insurance” includes the Children’s Health Insurance Program (CHIP), military insurance, Indian Health Service, and any other type of health insurance not mentioned elsewhere.
§ Estimates with 95% confidence intervals > 20 may not be reliable.
¶ Includes percentages receiving Tdap vaccine at age ≥10 years.
**Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.
††Statistically significant difference (p<0.05) in estimated vaccination coverage by health insurance status; referent group was adolescents with private insurance only.
§§ ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.
¶¶HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.
*** HPV UTD includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
††† In July 2020, ACIP revised recommendations for HepA vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received HepA vaccine at any age. MMWR Recomm Rep 2020;69(No. RR-5):1–38.
§§§ By parent/guardian report or provider records.